- Asenapine (Saphris, Merck & Co., Inc.)
- Bepotastine (Bepreve, ISTA Pharmaceuticals)
- Dronedarone (Multaq, Sanofi-aventis)
- Liraglutide (Victoza, Novo Nordisk)
- Tocilizumab (Actemra, Genentech)
- Ustekinumab (Stelara, Centocor Ortho Biotech)
- For details see http://www.medscape.com/viewarticle/731720
New Drug Review 2010
Wednesday, November 17, 2010
New molecular entities (NMEs) approved in 2010
Subscribe to:
Post Comments (Atom)
Free Books, powerpoint presentations, teaching tools and resources and drug information
-
-
Is Vitapulse a Scam? - The heart is a vital organ of the body and it plays major roles in its general functioning. Proper healthcare should be taken to ensure the heart functio...8 years ago
-
Comparative Effect of Agomelatine versus Escitalopram on Glycemic Control and Symptoms of Depression in Patients with Type 2 Diabetes Mellitus and Depression - Kumar K, Salman MT, Shukla V, Ahmad A, Verma V K, Rizvi D A and Kohli A: Comparative Effect of Agomelatine versus Escitalopram on Glycemic Control and Symp...8 years ago
-
Ranking of Indian Repositories - Ranking of Indian Repositories based on Ranking of Web of World Repositories, January 2009 Edition. World Ranking among all types of Repositories ...15 years ago
-
For Computer-lOvErS - *Antivirus SofTwArEs* Norton 360 (Up To 12 Years Key) Norton AntiVirus 2008 AVG Antivirus Panda.Antivirus NOD32 Antivirus Kingsoft Antivirus Kaspersky...15 years ago
-
Contemporary Targeted Therapies in Rheumatology - Publisher: Informa Healthcare Number Of Pages: 636 Publication Date: 2007-10-24 ISBN-10 / ASIN: 1841844845 ISBN-13 / EAN: 9781841844848 Binding: Hardcover ...15 years ago
-
-
-
-
-
-
-
Posts
No comments:
Post a Comment
Add your comment